16.90
price up icon5.03%   0.81
after-market Dopo l'orario di chiusura: 16.89 -0.010 -0.06%
loading
Precedente Chiudi:
$16.09
Aprire:
$16.12
Volume 24 ore:
1.74M
Relative Volume:
0.97
Capitalizzazione di mercato:
$2.34B
Reddito:
$181.74M
Utile/perdita netta:
$-143.97M
Rapporto P/E:
-12.16
EPS:
-1.39
Flusso di cassa netto:
$9.60M
1 W Prestazione:
+7.92%
1M Prestazione:
+3.05%
6M Prestazione:
-13.99%
1 anno Prestazione:
-32.99%
Intervallo 1D:
Value
$15.98
$16.98
Intervallo di 1 settimana:
Value
$15.31
$16.98
Portata 52W:
Value
$9.57
$30.41

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name
Nome
Arrowhead Pharmaceuticals Inc
Name
Telefono
626-696-4702
Name
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Name
Dipendente
609
Name
Cinguettio
@ArrowheadPharma
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
ARWR's Discussions on Twitter

Confronta ARWR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ARWR
Arrowhead Pharmaceuticals Inc
16.90 2.34B 181.74M -143.97M 9.60M -1.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-06-05 Iniziato Goldman Neutral
2023-12-04 Iniziato BofA Securities Buy
2023-09-19 Iniziato Citigroup Neutral
2023-07-21 Iniziato TD Cowen Outperform
2023-05-12 Downgrade SVB Securities Outperform → Market Perform
2023-04-26 Iniziato SMBC Nikko Outperform
2023-04-12 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-21 Iniziato Bernstein Mkt Perform
2022-09-09 Iniziato Morgan Stanley Equal-Weight
2022-05-11 Aggiornamento Robert W. Baird Neutral → Outperform
2022-01-19 Ripresa Goldman Buy
2021-08-06 Reiterato Chardan Capital Markets Buy
2021-06-04 Ripresa Robert W. Baird Neutral
2021-02-05 Reiterato H.C. Wainwright Buy
2020-12-21 Downgrade Robert W. Baird Outperform → Neutral
2020-12-16 Iniziato UBS Buy
2020-11-19 Iniziato Citigroup Buy
2020-05-13 Iniziato RBC Capital Mkts Outperform
2020-05-08 Aggiornamento Oppenheimer Perform → Outperform
2020-04-15 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-03-24 Aggiornamento SVB Leerink Underperform → Mkt Perform
2020-03-17 Iniziato Goldman Neutral
2020-01-21 Iniziato SVB Leerink Underperform
2019-12-13 Iniziato Oppenheimer Perform
2019-11-29 Reiterato Chardan Capital Markets Buy
2019-11-27 Reiterato B. Riley FBR Buy
2019-11-25 Aggiornamento Robert W. Baird Neutral → Outperform
2019-10-24 Downgrade Robert W. Baird Outperform → Neutral
2019-10-22 Reiterato Chardan Capital Markets Buy
2019-10-03 Iniziato Robert W. Baird Outperform
2018-09-07 Aggiornamento B. Riley FBR Neutral → Buy
2018-09-06 Reiterato Chardan Capital Markets Buy
2018-08-08 Reiterato Cantor Fitzgerald Overweight
2018-07-02 Reiterato Chardan Capital Markets Buy
Mostra tutto

Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie

pulisher
Jun 12, 2025

Where are the Opportunities in (ARWR) - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail

Jun 12, 2025
pulisher
Jun 12, 2025

GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 08, 2025

California State Teachers Retirement System Reduces Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to “Buy” at Wall Street Zen - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey

Jun 05, 2025
pulisher
Jun 04, 2025

Arrowhead at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga

Jun 04, 2025
pulisher
Jun 02, 2025

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 31, 2025
pulisher
May 30, 2025

SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - BioSpace

May 29, 2025
pulisher
May 24, 2025

Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com

May 24, 2025
pulisher
May 23, 2025

What is HC Wainwright’s Estimate for ARWR FY2025 Earnings? - Defense World

May 23, 2025
pulisher
May 22, 2025

HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World

May 22, 2025
pulisher
May 21, 2025

Arrowhead at RBC Conference: Strategic Insights on Drug Pipeline By Investing.com - Investing.com India

May 21, 2025
pulisher
May 20, 2025

Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

May 19, 2025
pulisher
May 18, 2025

Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 18, 2025

B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World

May 18, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

May 17, 2025
pulisher
May 17, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - Defense World

May 17, 2025
pulisher
May 16, 2025

ARWR: Multiple Value Drivers for Long-Term Growth - Research Tree

May 16, 2025
pulisher
May 16, 2025

Q3 Earnings Forecast for ARWR Issued By Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 16, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

May 16, 2025
pulisher
May 15, 2025

Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks

May 15, 2025
pulisher
May 15, 2025

Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum - MSN

May 15, 2025
pulisher
May 15, 2025

ARWR July 18th Options Begin Trading - Nasdaq

May 15, 2025
pulisher
May 15, 2025

ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Citigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $17.00 - Defense World

May 15, 2025
pulisher
May 14, 2025

UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings Beat - Defense World

May 14, 2025
pulisher
May 14, 2025

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus

May 14, 2025
pulisher
May 13, 2025

RBC cuts Arrowhead Pharma target to $40; keeps Outperform By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating - marketscreener.com

May 13, 2025

Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Arrowhead Pharmaceuticals Inc Azioni (ARWR) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Anzalone Christopher Richard
Chief Executive Officer
Apr 10 '25
Sale
10.87
50,000
543,500
3,972,055
Anzalone Christopher Richard
Chief Executive Officer
Apr 09 '25
Sale
10.07
40,322
406,145
4,022,055
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):